TY - JOUR
T1 - The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma
AU - Goldschmidt, Neta
AU - Darawshy, Fares
AU - Kleinstern, Geffen
AU - Slyusarevsky, Elena
AU - Pogrebijski, Galina
AU - Krichevsky, Svetlana
AU - Ben-Yehuda, Dina
AU - Gatt, Moshe E.
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/1/2
Y1 - 2017/1/2
N2 - We retrospectively studied the prognostic role of molecular (gene rearrangement, GRR) bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL, 424 patients) and in peripheral T-cell lymphoma (PTCL, 67 patients). When correlating BM GRR to histological findings at diagnosis, the GRR test was more sensitive (p = 0.036) but less specific (p < 0.0001) in PTCL than in DLBCL. For DLBCL (but not PTCL), a positive BM GRR correlated with advanced stage (p = 0.0001) and high IPI (p = 0.002), and worsened the progression free survival (PFS) (p = 0.05) and overall survival (OS) (p = 0.01), irrespective of rituximab treatment. Histologic negative/GRR positive cases had worse PFS/OS (p < 0.0001) than histologic/GRR double negative cases, however BM GRR was not an independent prognostic survival factor. End-of-treatment BM GRR did not predict survival. We conclude that BM GRR is unjustified as a prognostic tool for PTCL and should be reserved for a subset of DLBCL patients with negative histology of the BM.
AB - We retrospectively studied the prognostic role of molecular (gene rearrangement, GRR) bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL, 424 patients) and in peripheral T-cell lymphoma (PTCL, 67 patients). When correlating BM GRR to histological findings at diagnosis, the GRR test was more sensitive (p = 0.036) but less specific (p < 0.0001) in PTCL than in DLBCL. For DLBCL (but not PTCL), a positive BM GRR correlated with advanced stage (p = 0.0001) and high IPI (p = 0.002), and worsened the progression free survival (PFS) (p = 0.05) and overall survival (OS) (p = 0.01), irrespective of rituximab treatment. Histologic negative/GRR positive cases had worse PFS/OS (p < 0.0001) than histologic/GRR double negative cases, however BM GRR was not an independent prognostic survival factor. End-of-treatment BM GRR did not predict survival. We conclude that BM GRR is unjustified as a prognostic tool for PTCL and should be reserved for a subset of DLBCL patients with negative histology of the BM.
KW - Gene rearrangement
KW - bone marrow
KW - diffuse large B-cell lymphoma
KW - peripheral T-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84992026018&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1201569
DO - 10.1080/10428194.2016.1201569
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27756163
AN - SCOPUS:84992026018
SN - 1042-8194
VL - 58
SP - 45
EP - 52
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -
